Weekly Digest – July 2026 Weekly Digest – July 2026 30 June 2026: CSPC initiates phase 3 trial of SYS-6010 in combination with Enlonstobart in resected stage II–IIIB NSCLC CSPC Pharmaceutical Group has initiated the phase 3 SYS6010-015 trial in […]
Weekly Digest – June 2026 Weekly Digest – June 2026 15 June 2026: Akeso’s HER3 ADC AK138D1 in combination with Ivonescimab phase 1/2 Breast cancer trial enrolls first patient Akeso has announced the enrollment of the first patient in the […]
Weekly Digest – June 2026 Weekly Digest – June 2026 08 June 2026: Merck and Gilead discontinue phase 3 KEYNOTE-D46/EVOKE-03 study of Trodelvy plus Keytruda in 1L metastatic NSCLC Merck and Gilead have announced the discontinuation of the phase 3 […]
Weekly Digest – June 2026 Weekly Digest – June 2026 30 May 2026: MediLink Therapeutics announces B7-H3 ADC YL201 met primary endpoint in phase 3 Nasopharyngeal carcinoma study MediLink Therapeutics has announced that its B7-H3-targeted ADC YL201, successfully met the […]
Weekly Digest – May 2026 Weekly Digest – May 2026 18 May 2026: TroFuse-005 trial evaluating Sacituzumab Tirumotecan met primary endpoints of OS and PFS in certain patients with advanced or recurrent Endometrial cancer Merck & Co. announced that the […]
Weekly Digest – May 2026 Weekly Digest – May 2026 19 May 2026: Hengrui announces phase 3 trial of HER3 ADC SHR-A2009 for EGFR-mutant advanced NSCLC met primary endpoint of PFS Jiangsu Hengrui Pharmaceuticals announced that its HER3-directed ADC SHR-A2009 […]
Weekly Digest – May 2026 Weekly Digest – May 2026 21 May 2026: Kelun-Biotech announces phase 3 trial of Sacituzumab Tirumotecan versus Chemotherapy as 1L treatment for advanced TNBC met primary endpoint of PFS Sichuan Kelun-Biotech Biopharmaceutical announced that the […]
Weekly Digest – April 2026 Weekly Digest – April 2026 23 April 2026: Mabwell initiates phase 3 clinical study of its Nectin-4 targeting ADC 9MW2821 for the treatment of TNBC Mabwell announced the initiation of a Phase 3 clinical trial […]
Weekly Digest – March 2026 Weekly Digest – March 2026 20 March 2026: Alphamab Oncology announces the first patient dosed in a Phase 3 clinical study for triple-negative breast cancer of TROP2/HER3 bispecific ADC JSKN016 Alphamab Oncology has reached a […]
Weekly Digest – March 2026 Weekly Digest – March 2026 16 March 2026: CytomX’s Varsetatug Masetecan continues to demonstrate positive data supporting potential as a new treatment option in late-line colorectal cancer CytomX Therapeutics has strengthened its position in next-generation […]
